Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary DRP technology to develop precision medicine for patients with high unmet medical needs, and its lead drug Stenoparib is showing promise in clinical trials for advanced recurrent ovarian cancer. Although concerns about long development timelines and high risks remain, strong growth prospects and a reasonable valuation make Allarity Therapeutics an attractive investment opportunity. In its Q1 2026 fiscal results, the company reported minimal revenue but managed a smaller net loss than expected, indicating promising financial management.

Bears say

Allarity Therapeutics is facing significant risks, as its balance sheet and liquidity are at risk due to only having $15 million in cash and $1 million in debt. There is potential for failure in demonstrating the safety and efficacy of its product candidates, along with potential challenges in gaining and maintaining regulatory approvals and commercializing its product. Market competition and changing macroeconomic factors also pose potential challenges, leading to a negative outlook on the stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.